Escherichia coli Nissle 1917 Antagonizes Candida albicans Growth and Protects Intestinal Cells from C. albicans-Mediated Damage

Candida albicans is a pathobiont of the gastrointestinal tract. It can contribute to the diversity of the gut microbiome without causing harmful effects. When the immune system is compromised, C. albicans can damage intestinal cells and cause invasive disease. We hypothesize that a therapeutic approach against C. albicans infections can rely on the antimicrobial properties of probiotic bacteria. We investigated the impact of the probiotic strain Escherichia coli Nissle 1917 (EcN) on C. albicans growth and its ability to cause damage to intestinal cells. In co-culture kinetic assays, C. albicans abundance gradually decreased over time compared with C. albicans abundance in the absence of EcN. Quantification of C. albicans survival suggests that EcN exerts a fungicidal activity. Cell-free supernatants (CFS) collected from C. albicans-EcN co-culture mildly altered C. albicans growth, suggesting the involvement of an EcN-released compound. Using a model of co-culture in the presence of human intestinal epithelial cells, we further show that EcN prevents C. albicans from damaging enterocytes both distantly and through direct contact. Consistently, both C. albicans’s filamentous growth and microcolony formation were altered by EcN. Taken together, our study proposes that probiotic-strain EcN can be exploited for future therapeutic approaches against C. albicans infections.

[1]  Jakob L. Sprague,et al.  From intestinal colonization to systemic infections: Candida albicans translocation and dissemination , 2022, Gut microbes.

[2]  T. Sugita,et al.  Candida albicans Promotes the Antimicrobial Tolerance of Escherichia coli in a Cross-Kingdom Dual-Species Biofilm , 2022, Microorganisms.

[3]  E. Ryan,et al.  Integrated Profiling of Gram-Positive and Gram-Negative Probiotic Genomes, Proteomes and Metabolomes Revealed Small Molecules with Differential Growth Inhibition of Antimicrobial-Resistant Pathogens , 2022, Journal of dietary supplements.

[4]  M. Ebert,et al.  The gut virome: A new microbiome component in health and disease , 2022, EBioMedicine.

[5]  Sascha Schäuble,et al.  Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity , 2022, Nature Communications.

[6]  T. Köllner,et al.  Augmented Enterocyte Damage During Candida albicans and Proteus mirabilis Coinfection , 2022, Frontiers in Cellular and Infection Microbiology.

[7]  S. Leibundgut-Landmann,et al.  Immunosurveillance of Candida albicans commensalism by the adaptive immune system , 2022, Mucosal Immunology.

[8]  S. Jawhara.  How Gut Bacterial Dysbiosis Can Promote Candida albicans Overgrowth during Colonic Inflammation , 2022, Microorganisms.

[9]  Wendy W. K. Mok,et al.  Probiotic Escherichia coli Nissle 1917 inhibits bacterial persisters that survive fluoroquinolone treatment , 2022, Journal of applied microbiology.

[10]  M. Darwish,et al.  Health Benefits of Postbiotics Produced by E. coli Nissle 1917 in Functional Yogurt Enriched with Cape Gooseberry (Physalis peruviana L.) , 2022, Fermentation.

[11]  O. Pedersen,et al.  Gut microbiota in human metabolic health and disease , 2020, Nature Reviews Microbiology.

[12]  J. Kay,et al.  Bacteria Modify Candida albicans Hypha Formation, Microcolony Properties, and Survival within Macrophages , 2020, mSphere.

[13]  M. Gresnigt,et al.  The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. , 2020, Current opinion in microbiology.

[14]  U. Dobrindt,et al.  Metabolomics Study on Pathogenic and Non-pathogenic E. coli with Closely Related Genomes with a Focus on Yersiniabactin and Its Known and Novel Derivatives , 2020, Metabolites.

[15]  M. Gresnigt,et al.  Keeping Candida commensal: how lactobacilli antagonize pathogenicity of Candida albicans in an in vitro gut model , 2019, Disease Models & Mechanisms.

[16]  I. Jacobsen,et al.  Fungal-Bacterial Interactions in Health and Disease , 2019, Pathogens.

[17]  Fourie,et al.  Beyond Antagonism: The Interaction Between Candida Species and Pseudomonas aeruginosa , 2019, Journal of fungi.

[18]  David G. E. Smith,et al.  Substantial Extracellular Metabolic Differences Found Between Phylogenetically Closely Related Probiotic and Pathogenic Strains of Escherichia coli , 2019, Front. Microbiol..

[19]  B. Hube,et al.  Intestinal epithelial cells and T cells differentially recognize and respond to Candida albicans yeast and hypha , 2018, European journal of immunology.

[20]  Jun Yu,et al.  Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection , 2018, Nature Communications.

[21]  Rohitash Kumar,et al.  Candida albicans Sfl1/Sfl2 regulatory network drives the formation of pathogenic microcolonies , 2018, PLoS pathogens.

[22]  A. Koh,et al.  Adaptation of Candida albicans During Gastrointestinal Tract Colonization , 2018, Current Clinical Microbiology Reports.

[23]  M. Schaller,et al.  Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers , 2018, mBio.

[24]  H. El‐Nezami,et al.  Effects of Lactobacillus rhamnosus GG and Escherichia coli Nissle 1917 Cell-Free Supernatants on Modulation of Mucin and Cytokine Secretion on Human Intestinal Epithelial HT29-MTX Cells. , 2018, Journal of food science.

[25]  P. De Luca,et al.  Morphofunctional properties of a differentiated Caco2/HT-29 co-culture as an in vitro model of human intestinal epithelium , 2018, Bioscience reports.

[26]  Peter Belenky,et al.  Microbial competition between Escherichia coli and Candida albicans reveals a soluble fungicidal factor , 2018, Microbial cell.

[27]  M. Lorenz,et al.  Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of Candida albicans , 2017, Proceedings of the National Academy of Sciences.

[28]  Aleksandra A. Kolodziejczyk,et al.  Dysbiosis and the immune system , 2017, Nature Reviews Immunology.

[29]  B. Hube,et al.  Enemies and brothers in arms: Candida albicans and gram‐positive bacteria , 2016, Cellular microbiology.

[30]  U. Sonnenborn.  Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties. , 2016, FEMS microbiology letters.

[31]  D. Underhill,et al.  Immunological Consequences of Intestinal Fungal Dysbiosis. , 2016, Cell host & microbe.

[32]  L. Samaranayake,et al.  Probiotics as Antifungals in Mucosal Candidiasis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  M. P. Francino,et al.  Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances , 2016, Front. Microbiol..

[34]  Martina Sassone-Corsi,et al.  No Vacancy: How Beneficial Microbes Cooperate with Immunity To Provide Colonization Resistance to Pathogens , 2015, The Journal of Immunology.

[35]  G. Rogler,et al.  Probiotic Escherichia coli Nissle 1917 and Commensal E. coli K12 Differentially Affect the Inflammasome in Intestinal Epithelial Cells , 2014, Digestion.

[36]  L. Ferguson,et al.  The Probiotic Escherichia coli Nissle 1917 Reduces Pathogen Invasion and Modulates Cytokine Expression in Caco-2 Cells Infected with Crohn's Disease-Associated E. coli LF82 , 2011, Applied and Environmental Microbiology.

[37]  M. Schembri,et al.  A virulent parent with probiotic progeny: comparative genomics of Escherichia coli strains CFT073, Nissle 1917 and ABU 83972 , 2010, Molecular Genetics and Genomics.

[38]  K. Fellermann,et al.  Induction of Human β-Defensin 2 by the Probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin , 2007, Infection and Immunity.

[39]  Ronald W. Davis,et al.  Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions , 2007, Nature Genetics.

[40]  S. Vylkova,et al.  Human β-Defensins Kill Candida albicans in an Energy-Dependent and Salt-Sensitive Manner without Causing Membrane Disruption , 2006, Antimicrobial Agents and Chemotherapy.

[41]  Carmen Buchrieser,et al.  Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells , 2006, Science.

[42]  R. Geffers,et al.  The host response to the probiotic Escherichia coli strain Nissle 1917: Specific up-regulation of the proinflammatory chemokine MCP-1 , 2005, BMC Medical Genetics.

[43]  S. Nuding,et al.  NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: a Novel Effect of a Probiotic Bacterium , 2004, Infection and Immunity.

[44]  K. Hantke,et al.  The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. , 2003, Microbiology.

[45]  H. Naoki,et al.  Yatakemycin, a novel antifungal antibiotic produced by Streptomyces sp. TP-A0356. , 2003, The Journal of antibiotics.

[46]  R. Darouiche,et al.  Virulence Properties of Escherichia coli83972, a Prototype Strain Associated with Asymptomatic Bacteriuria , 1999, Infection and Immunity.

[47]  S. Hockertz.  Augmentation of host defence against bacterial and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. , 1997, Arzneimittel-Forschung.

[48]  H. Mobley,et al.  Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains , 1990, Infection and immunity.